ArticleEuropean journal of nuclear medicine and molecular imaging2026
Dual-tracer PET/CT and cocktail therapy with [
Article in European journal of nuclear medicine and molecular imaging, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThere remains an unmet need for G3 neuroendocrine tumor (NET) treatment, and the therapeutic efficacy of peptide receptor radionuclide therapy (PRRT) is suboptimal. PURPOSE: To investigate the feasibility and efficacy of cocktail therapy, combining co-administered [177Lu]Lu-Fibroblast activation protein (FAP) 2286 and [177Lu]Lu(lutetium)-(DOTA0, Tyr3) octreotide ([177Lu]Lu-DOTATATE), in eligible patients with G3 NET screened by dual-tracer PET/CT.
methodsThis single-center prospective study enrolled adults with histologically confirmed G3 NET (Ki67 ≥20%). Participants underwent dual-tracer PET/CT with [68Ga]Ga(gallium)-DOTATATE and [68Ga]Ga-FAP2286. Based on imaging findings, eligible participants received cocktail therapy combining co-administered [177Lu]Lu-FAP2286 and [177Lu]Lu-DOTATATE with a total dose of approximately 7.4 GBq per cycle. Imaging response was assessed by Positron Emission Tomography Response Criteria in Solid Tumors (PERCIST1.0), clinical response by European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30), and adverse events (AEs) were graded by Common Terminology Criteria for Adverse Events (CTCAE v5.0).
resultsTotal 23 patients (15 males, aged 52 [37-66] median [IQR]) were enrolled and 7 received 2–6 cycles of cocktail therapy. For liver metastases, [68Ga]Ga-FAP2286 exhibited a higher sensitivity (82% vs 62%) and TBRliver (4.7±2.0 vs 2.9±2.3) compared to [68Ga]Ga-DOTATATE (P=0.036). According to PERCIST 1.0, 5 participants achieved a partial metabolic response, yielding an objective response rate of 71%. The 1-year survival rate was 86%, with median overall survival and progression-free survival both exceeding 15 months. Furthermore, 71% of participants experienced an improvement in global health status. The therapy was well-tolerated, with no treatment-related deaths or Grade 3/4 adverse events.
conclusionIn conclusion, this prospective study demonstrates that dual-tracer PET/CT effectively identifies G3 NET patients suitable for subsequent cocktail targeted radionuclide therapy. The subsequent cocktail therapy of [177Lu]Lu-FAP2286 and [177Lu]Lu-DOTATATE yielded promising efficacy and safety profile. This theranostic approach represents a promising strategy for treating G3 NET.
Indexed as
Identifiers
41840048What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.